Welcome to our dedicated page for VERTEX PHARMACEUTICALS / MA SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERTEX PHARMACEUTICALS / MA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERTEX PHARMACEUTICALS / MA's regulatory disclosures and financial reporting.
Vertex Pharmaceuticals executive vice president and CMO Carmen Bozic reported two stock award acquisitions of common stock on 01/22/2026. The filings show grant/award acquisitions of 7,866 and 3,467 shares. Footnotes describe these as earned performance shares from performance stock unit awards granted on 02/01/2023 and 02/12/2025, after the management development and compensation committee certified performance-goal attainment on 01/22/2026, with vesting dates in February 2026. After these awards, she directly holds 44,002 Vertex shares.
Vertex Pharmaceuticals executive Jonathan Biller reported the acquisition of 9,068 shares of common stock through earned performance awards. On 01/22/2026, he received 6,294 shares tied to a performance stock unit grant from 02/01/2023 and 2,774 shares tied to a grant from 02/12/2025, both at a price of $0 per share. The company’s management development and compensation committee certified performance attainment on 01/22/2026. The first block of shares is scheduled to vest on 02/13/2026, and the second will vest in installments beginning on 02/24/2026. Following these awards, Biller directly beneficially owns 24,374 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported the vesting of performance-based stock awards. On January 22, 2026, he acquired 3,934 shares of Vertex common stock tied to a performance stock unit grant from February 1, 2023, and 3,883 shares tied to a performance stock unit grant from February 12, 2025, both at a price of $0 per share as earned performance shares.
The compensation committee certified achievement of the performance goals on January 22, 2026. The shares from the 2023 grant are scheduled to vest on February 13, 2026, while the 2025 grant will vest in installments beginning on February 24, 2026. Following these transactions, Atkinson directly holds 24,669 shares of Vertex common stock.
Vertex Pharmaceuticals executive Kristen Ambrose, SVP & Chief Accounting Officer, reported the acquisition of company stock tied to performance awards. On 01/22/2026, Ambrose acquired 2,950 shares of Vertex common stock at $0 per share from an earned performance stock unit award originally granted on 02/01/2023, increasing direct holdings to 10,795 shares.
On the same date, Ambrose also acquired 1,300 additional shares at $0 per share from a separate performance stock unit award granted on 02/12/2025, bringing direct ownership to 12,095 shares. The filing explains that these are earned performance shares following the compensation committee’s certification of performance-goal attainment on 01/22/2026, with the related shares scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.
Vertex Pharmaceuticals executive David Altshuler reported stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,328 shares, each at a price of $0 per share, reflecting earned performance shares from prior performance stock unit awards. These awards were originally granted on 02/01/2023 and 02/12/2025 and included performance-vesting requirements that the company’s management development and compensation committee certified as achieved on 01/22/2026. After these transactions, Altshuler directly owned 34,477 shares of Vertex common stock. The 7,866-share portion is scheduled to vest on 02/13/2026, and the 3,328-share portion will vest in installments beginning on 02/24/2026.
Vertex Pharmaceuticals director Suketu Upadhyay reported an acquisition of derivative equity on Form 4. On 01/15/2026, he acquired 80.316 deferred stock units at a price of $443.56 per unit, bringing his total holdings of these derivative securities to 2,718.648 units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock upon the earliest of Mr. Upadhyay’s termination from the board, a change of control of the company, or his disability or death. This filing reflects a change in his deferred equity position rather than an immediate cash transaction in Vertex common shares.
Vertex Pharmaceuticals director Bruce I. Sachs reported an automatic grant of deferred stock units tied to his board service. On January 15, 2026, he acquired 107.088 deferred stock units at a reference price of $443.56 per unit, bringing his total to 15,564.521 deferred stock units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock at the earliest of Sachs leaving the board, a change of control of the company, or his disability or death. This filing reflects equity-based compensation rather than an open-market stock purchase or sale.
Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported selling 4,500 shares of Vertex common stock on 01/07/2026 at a price of $474.99 per share. After this transaction, she beneficially owned 42,293 shares, all held directly.
The filing notes that the sale was made pursuant to Dr. Tatsis’ company-approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. Such plans are pre-arranged programs that allow insiders to sell stock according to preset terms, helping them diversify holdings while addressing concerns about trading on material nonpublic information.
Vertex Pharmaceuticals executive Charles F. Jr. Wagner, EVP, CO & FO, reported an option exercise and share sale in company stock. On 01/06/2026 he exercised 9,532 stock options at an exercise price of $189.38 per share, receiving the same number of Vertex common shares. That same day, he sold 9,532 common shares at a price of $461 per share, a transaction coded as a sale. After these transactions, he directly owned 37,725 shares of Vertex common stock. The filing notes that the sale was made under Mr. Wagner’s company-approved Rule 10b5-1 trading plan, which was entered into on 05/09/2025, and that the exercised options were fully vested.
Vertex Pharmaceuticals insider Ourania Tatsis has filed a notice to sell common stock under Rule 144. The filing covers 4,500 shares of Vertex common stock to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $2,137,455.00, against 253,718,831 shares outstanding.
The shares to be sold were acquired mainly through restricted stock vesting on several dates in 2021 and 2024, plus a small purchase through the employee stock purchase plan in May 2024. The notice also reports that Tatsis sold 4,500 Vertex common shares on 12/03/2025 for gross proceeds of $2,024,955.40. By signing, the seller represents not knowing any undisclosed material adverse information about the company’s operations.